Factory 99% Edoxaban Tosylate Powder CAS 1229194-11-9 Chemical Intermediate Edoxaban Tosylate

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A905
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Edoxaban Tosylate
• CAS: 1229194-11-9
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Edoxaban tosylate
Appearance	White Powder
CAS NO.	1229194-11-9
Storage	Keep in a cool, dry, dark location

 

Edoxaban tosylate is an orally active, highly potent, selective, and direct inhibitor of Factor Xa (FXa). It is a salt form of edoxaban, a small molecule anticoagulant, combined with p-toluenesulfonic acid.

 

1. Prevention of Thromboembolic Diseases: Edoxaban tosylate is used for the prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (AF). It is also indicated for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as the prevention of recurrent DVT and PE.

2. Cardiovascular Care: In the cardiovascular field, edoxaban tosylate offers an alternative to other anticoagulants for patients requiring long-term anticoagulation therapy. Its oral administration and predictable pharmacokinetics make it a convenient treatment option.

3. Research and Development: Edoxaban tosylate is also used in research settings to study the pharmacological properties and clinical efficacy of FXa inhibitors in preventing and treating thromboembolic disorders.

1. Inhibition of FXa: Edoxaban tosylate specifically inhibits FXa, a key enzyme in the coagulation cascade. By blocking FXa, it prevents the conversion of prothrombin to thrombin, thereby reducing the formation of blood clots.

2. Anticoagulant Effect: The anticoagulant effect of edoxaban tosylate is dose-dependent and results in prolonged prothrombin time (PT) and activated partial thromboplastin time (APTT). This helps in preventing the formation of unwanted blood clots.

3. Reduction of Thromboembolic Risk: By inhibiting FXa and reducing clot formation, edoxaban tosylate significantly lowers the risk of thromboembolic events, such as stroke, myocardial infarction, and venous thromboembolism, in patients with atrial fibrillation or other conditions predisposing them to thrombosis.